Endometrial cancer （EC） is the most common gynecologic malignancy in developed countries，and its incidence has been steadily increasing in recent years in China，with a trend toward younger onset. With the updates of international guidelines，the diagnosis，treatment and follow-up of EC have entered an era of high standardization. However，EC exhibits marked biological heterogeneity in clinical practice，and reliance solely on clinicopathological factors is insufficient in accurately identifying prognostic differences and predicting therapeutic benefit. Therefore，the introduction of individualized strategies on the basis of standardized management has become an inevitable trend. The TCGA classification has established the framework for the molecular era of EC，with distinct molecular subtypes showing significant prognostic differences and providing guidance for the selection of chemotherapy，radiotherapy and immunotherapy. In recent years，rapid advances in researches on the tumor immune microenvironment （TIME） have further clarified the impact of different immune infiltration patterns on treatment responses. This review summarizes the current status and recent advances in standardized diagnosis and treatment of EC，with a particular focus on individualized strategies driven by molecular typing，immune characteristics，and multi-omics integration，aiming to provide references for clinical practice.